1. Home
  2. BL vs AVLN Comparison

BL vs AVLN Comparison

Compare BL & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BlackLine Inc.

BL

BlackLine Inc.

HOLD

Current Price

$30.26

Market Cap

1.7B

Sector

Technology

ML Signal

HOLD

Logo Avalyn Pharma Inc. Common Stock

AVLN

Avalyn Pharma Inc. Common Stock

N/A

Current Price

$39.31

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BL
AVLN
Founded
2001
N/A
Country
United States
United States
Employees
1850
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.3B
IPO Year
2016
2026

Fundamental Metrics

Financial Performance
Metric
BL
AVLN
Price
$30.26
$39.31
Analyst Decision
Buy
Analyst Count
13
0
Target Price
$56.62
N/A
AVG Volume (30 Days)
1.1M
190.5K
Earning Date
05-05-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.40
N/A
Revenue
$177,031,000.00
N/A
Revenue This Year
$12.62
N/A
Revenue Next Year
$10.90
N/A
P/E Ratio
$78.40
N/A
Revenue Growth
43.78
N/A
52 Week Low
$24.70
$24.90
52 Week High
$59.57
$39.99

Technical Indicators

Market Signals
Indicator
BL
AVLN
Relative Strength Index (RSI) 51.46 73.88
Support Level $29.23 $26.38
Resistance Level $31.14 N/A
Average True Range (ATR) 1.57 2.24
MACD -0.15 1.04
Stochastic Oscillator 46.70 92.56

Price Performance

Historical Comparison
BL
AVLN

About BL BlackLine Inc.

BlackLine Inc is engaged in providing financial accounting close solutions delivered as Software as a Service (SaaS). The Company's solutions enable its customers to address various aspects of their critical processes, including financial close & consolidation, intercompany accounting, and invoice-to-cash. The majority of the revenue of the company is earned in the United States.

About AVLN Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

Share on Social Networks: